RT Journal Article
SR Electronic
T1 Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 64
OP 66
VO 55
IS 1
A1 Longhurst, H J
A1 O'Grady, C
A1 Evans, G
A1 De Lord, C
A1 Hughes, A
A1 Cavenagh, J
A1 Helbert, M R
YR 2002
UL http://jcp.bmj.com/content/55/1/64.abstract
AB Aims: To review our experience of anti-D immunoglobulin for immune thrombocytopenia (ITP) in patients with primary antibody deficiency. Methods/patients: A retrospective case notes review of four Rhesus positive patients with ITP and primary antibody deficiency, treated with anti-D. Patients were refractory to steroids and high dose intravenous immunoglobulin (IVIG). Two patients were previously splenectomised. Results: All patients responded to anti-D immunoglobulin. Improved platelet counts were sustained for at least three months. Side effects included a fall in haemoglobin in all cases; one patient required red blood cell transfusion. Two patients had transient neutropenia (< 1 × 109/litre). Conclusion: Anti-D immunoglobulin may be an effective treatment for antibody deficiency associated thrombocytopenia, even after splenectomy. Anti-D immunoglobulin may have considerable clinical advantages in this group of patients, where treatments resulting in further immunosuppression are relatively contraindicated.